Constrained Optimization for Pneumococcal Vaccination in Brazil.
Brazil
economic evaluation
optimization
pneumococcal vaccination
Journal
Value in health regional issues
ISSN: 2212-1102
Titre abrégé: Value Health Reg Issues
Pays: United States
ID NLM: 101592642
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
20
11
2019
revised:
02
10
2020
accepted:
12
11
2020
pubmed:
14
4
2021
medline:
1
12
2021
entrez:
13
4
2021
Statut:
ppublish
Résumé
To identify the most cost-efficient combination of pneumococcal vaccines in infants and aging adults for a 10-year period in Brazil. Constrained optimization (CO) prioritized 9 pneumococcal vaccine regimens according to their gain in quality-adjusted life-years (QALYs) and their related costs over a prespecified time horizon with defined constraints for 2 age groups, infants and aging adults. The analysis starts from the current universal infant vaccination of pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV), 2 primary and 1 booster dose at 2, 4, and 12 months, respectively. Key constraints are the fixed annual vaccine budget increase and the relative return on investment (ROI The CO analysis including all the constraints indicates that over 10 years the maximum extra health gain is 126 194 QALYs for an extra budget of $974 million Brazilian reals (ROI The study shows that with 4 constraints on budget, time horizon, vaccine coverage, and cost efficiency, a CO analysis could identify the most cost-efficient overall pneumococcal vaccination strategy for Brazil, allowing for limited vaccine budget increase while obtaining appropriate health gain.
Identifiants
pubmed: 33848895
pii: S2212-1099(21)00019-4
doi: 10.1016/j.vhri.2020.11.011
pii:
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
40-49Informations de copyright
Copyright © 2021. Published by Elsevier Inc.